SEC Form 4 · accession 0001209191-17-046024
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Jul 19, 2017
Accepted (ET)
Jul 21, 2017 · 7:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 19, 2017 | M | 25,500 | $96.87 | A | 156,967 | D | |
| Common Stock | Jul 19, 2017 | M | 38,250 | $109.14 | A | 195,217 | D | |
| Common Stock | Jul 19, 2017 | M | 14,875 | $131.89 | A | 210,092 | D | |
| Common Stock | Jul 19, 2017 | M | 10,775 | $91.05 | A | 220,867 | D | |
| Common Stock | Jul 19, 2017 | S | 60,400 | $161.00 | D | 160,467 | D | |
| Common Stock | Jul 19, 2017 | S | 29,000 | $162.67 | D | 131,467 | D | |
| Common Stock | Jul 21, 2017 | M | 2,125 | $131.89 | A | 133,592 | D | |
| Common Stock | Jul 21, 2017 | S | 2,125 | $159.00 | D | 131,467 | D | |
| Common Stock | Jul 21, 2017 | S | 10,150 | $161.68 | D | 121,317 | D | |
| Common Stock | Jul 21, 2017 | S | 200 | $161.72 | D | 121,117 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $96.87 | Jul 19, 2017 | M | 25,500 | D | — | Jul 14, 2024 | Common Stock | 25,500 | 8,500 | D |
| Stock Option (Right to Buy)F3 | $109.14 | Jul 19, 2017 | M | 38,250 | D | — | Feb 2, 2025 | Common Stock | 38,250 | 38,250 | D |
| Stock Option (Right to Buy)F4 | $131.89 | Jul 19, 2017 | M | 14,875 | D | — | Jul 20, 2025 | Common Stock | 14,875 | 19,125 | D |
| Stock Option (Right to Buy)F5 | $91.05 | Jul 19, 2017 | M | 10,775 | D | — | Feb 1, 2026 | Common Stock | 10,775 | 23,707 | D |
| Stock Option (Right to Buy)F4 | $131.89 | Jul 21, 2017 | M | 2,125 | D | — | Jul 20, 2025 | Common Stock | 2,125 | 17,000 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 07/15/2014.
- F3The option vests in 16 quarterly installments from 02/03/2015.
- F4The option vests in 16 quarterly installments from 07/21/2015.
- F5The option vests in 16 quarterly installments from 02/02/2016.